DPTX3186 in Wnt Pathway Activated Solid Tumors

Part of paid clinical trials in San Antonio, Texas.

Sponsor
Dewpoint Therapeutics
Study ID
NCT07312903
Phase
PHASE1
Status
Recruiting
Apply to this trial

Conditions

  • Solid Tumors

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • DPTX3186 — DRUG
    Once daily (single dose of study drug in the morning in fasted conditions) for 4 consecutive days (4 days on) and 3 days off in a cycle of 28 days

Study Details

This is a first-in human clinical study of DPTX3186 in subjects with Wnt-pathway activated solid tumors where no other treatments exist. The study will evaluate safety, pharmacokinetics, and initial activity of DPTX3186, as well as explore pharmacodynamic parameters to identify potential biomarkers of efficacy

Key Dates

Start date
Jan 31, 2026
Status verified
Jan 2026
Primary completion
May 31, 2028
Completion
Jun 30, 2028

Study Design

Enrollment
40 participants (estimated)
Allocation
NA
Intervention model
SEQUENTIAL
Primary purpose
TREATMENT

Arms

  • Experimental: Dose Escalation

Primary Outcome Measure

Incidence of treatment emergent adverse events and serious adverse events. [ Time Frame: Up to 36 Months ]

Locations (2)

FacilityCityStateZIPSite coordinators
NEXT San AntonioSan AntonioTexas78229
Jordan Georg
[email protected]
210-580-9521
NEXT VirginiaFairfaxVirginia22031
Maybelle de la Rosa
[email protected]
703-783-4518

Find similar trials in San Antonio, TX

By research site
NEXT San Antonio· San Antonio, TXNEXT Virginia· Fairfax, VA

Related Studies